Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy
| Autor: | Raphaël Porcher, Martine Bagot, Anne Caignard, Eve Maubec, Marie-Hélène Schlageter, Cécile Pagès, Wahid Boukouaci, Ryad Tamouza, Antoine Toubert, Barouyr Baroudjian, Bruno Cassinat, Hélène Moins-Teisserenc, Joana Felix, Céleste Lebbé, Laurence Homyrda |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Male Skin Neoplasms medicine.medical_treatment Cohort Studies 0302 clinical medicine Serum biomarkers Immunology and Allergy CTLA-4 Antigen Melanoma biology Antibodies Monoclonal Middle Aged 030220 oncology & carcinogenesis Cohort Female Immunotherapy Antibody medicine.drug Adult medicine.medical_specialty Immunology Ipilimumab Antineoplastic Agents S100 Calcium Binding Protein beta Subunit Antibodies 03 medical and health sciences Internal medicine medicine Biomarkers Tumor Humans Aged Monitoring Physiologic Neoplasm Staging Pharmacology L-Lactate Dehydrogenase business.industry Histocompatibility Antigens Class I Cancer medicine.disease Survival Analysis 030104 developmental biology CTLA-4 biology.protein business Follow-Up Studies |
| Zdroj: | International immunopharmacology. 40 |
| ISSN: | 1878-1705 |
| Popis: | Metastatic melanoma is a rapidly spreading cancer whose prognosis remains poor although important therapy advances in recent years. Ipilimumab, an anti-CTLA-4 immunotherapy used in advanced melanoma, is an effective immunotherapy alone or combined with other agents but with few predictive biomarkers of response. Here, we sought to analyze the potential of S100B, MIA, soluble MICA, anti-MICA antibodies and LDH as serum biomarkers of response and survival in a cohort of 77 advanced melanoma patients subjected to ipilimumab. Lower levels of S100B, and LDH at baseline and at weeks 3 and 6 correlated to a better response and survival. After multivariate analysis LDH maintained its independence at baseline and week 6, whereas S100B might be a useful tool for anti-CTLA-4 treatment monitoring after the first two doses of ipilimumab (W6). In addition, higher sMICA serum levels at baseline were associated with less frequency of irAEs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect